Trial Profile
A Multicenter, Randomized, Phase III Trial of Chemotherapy Followed by 6-month or 12-month Icotinib Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ICTAN
- 05 Jan 2023 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Aug 2018).
- 25 Aug 2018 Planned number of patients changed from 477 to 318.
- 19 Apr 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2020.